

COVID-19 Vaccines & Treatments									
Revised: January 1, 2022									
Submit claim for administration fee with the appropriate vaccine or monoclonal antibody CPT or HCPCS Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
COVID-19 Vaccines & Administration Codes									
1	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	Pfizer	PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension	59267-1000-01	\$0.00	1	12/11/2020	Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A
	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	Pfizer	PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension	59267-1000-02	\$0.00	1	12/11/2020	Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A
	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	Pfizer	PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension	59267-1000-03	\$0.00	1	12/11/2020	Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A
2	0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, first dose	Pfizer	N/A	N/A	\$40.00	1	12/11/2020	Report 0001A as the 1st dose administration for 91300
3	0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, second dose	Pfizer	N/A	N/A	\$40.00	1	12/11/2020	Report 0002A as the 2nd dose administration for 91300
4	0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, third dose	Pfizer	N/A	N/A	\$40.00	1	8/12/2021	Report 0003A as the 3rd dose administration for 91300
5	0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, booster dose	Pfizer	N/A	N/A	\$40.00	1	9/22/2021	Report 0004A as the booster dose administration for 91300
6	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-10	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-15	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-98	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-99	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
7	0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose	Moderna	N/A	N/A	\$40.00	1	12/18/2020	Report 0011A as the 1st dose administration for 91301
8	0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose	Moderna	N/A	N/A	\$40.00	1	12/18/2020	Report 0012A as the 1st dose administration for 91301
9	0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	Moderna	N/A	N/A	\$40.00	1	8/12/2021	Report 0013A as the 1st dose administration for 91301
10	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	Janssen	JANSSEN COVID-19 VACCINE 0.5ML Suspension	59676-0580-05	\$0.00	1	2/27/2021	Report 91303 with administration codes 0031A, 0034A

COVID-19 Vaccines & Treatments									
Revised: January 1, 2022									
Submit claim for administration fee with the appropriate vaccine or monoclonal antibody CPT or HCPCS Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	Janssen	JANSSEN COVID-19 VACCINE 0.5ML Suspension	59676-0580-15	\$0.00	1	2/27/2021	Report 91303 with administration codes 0031A,0034A
11	0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage,; single dose	Janssen	N/A	N/A	\$40.00	1	12/27/2021	Report 0031A as the single dose administration for 91303
12	0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage,; booster dose	Janssen	N/A	N/A	\$40.00	1	10/20/2021	Report 0034A as the booster dose administration for 91303
13	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Suspension	59267-1025-01	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Suspension	59267-1025-02	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Solution	59267-1025-03	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Solution	59267-1025-04	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
14	0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; first dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0051A as the first dose administration for 91305
15	0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; second dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0052A as the second dose administration for 91305
16	0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; third dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0053A as the third dose administration for 91305
17	0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; booster dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0054A as the booster dose administration for 91305
18	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-10	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A
	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-15	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A
	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-98	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A
	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-99	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A

COVID-19 Vaccines & Treatments									
Revised: January 1, 2022									
Submit claim for administration fee with the appropriate vaccine or monoclonal antibody CPT or HCPCS Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
19	0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	Moderna	N/A	N/A	\$40.00	1	10/20/2021	Report 0064A as the booster dose administration for 91306
20	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension	59267-1055-01	\$0.00	1	10/29/2021	Report 91307 with administration codes 0071A, 0072A
	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension	59267-1055-02	\$0.00	1	10/29/2021	Report 91307 with administration codes 0071A, 0072A
	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension	59267-1055-04	\$0.00	1	10/29/2021	Report 91307 with administration codes 0071A, 0072A
21	0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	Pfizer	N/A	N/A	\$40.00	1	10/29/2021	Report 0071A as the booster dose administration for 91307
22	0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	Pfizer	N/A	N/A	\$40.00	1	10/29/2021	Report 0072A as the booster dose administration for 91307
23	0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	Pfizer	N/A	N/A	\$40.00	1	1/3/2022	Report 0073A as the booster dose administration for 91307
24	M0201	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	N/A	N/A	N/A	\$35.50	1	6/8/2021	Report M0201 with any administration code
COVID-19 Monoclonal Antibodies & Administration Codes									
#	HCPCS	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
	J0248	Remdesivir, 1 mg	Gilead Sciences	VEKLURY 100MG Solution Reconstituted	61958-2901-01	\$5.20	200	12/23/2021	
1	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
2	M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	Regeneron	N/A	N/A	\$360.00	1	6/8/2021	Report M0240 with Q0240
3	M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	Regeneron	N/A	N/A	\$600.00	1	7/30/2021	Report M0241 with Q0240 for home/residence administration
4	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 1200MG Solution	61755-0024-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 1200MG Solution	61755-0025-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0035-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244

COVID-19 Vaccines & Treatments									
Revised: January 1, 2022									
Submit claim for administration fee with the appropriate vaccine or monoclonal antibody CPT or HCPCS Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0036-08	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0037-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0038-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0042-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0045-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
5	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0042-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0045-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
6	M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	Regeneron	N/A	N/A	\$360.00	1	12/1/2020	Report M0243 with Q0243/Q0244
7	M0244	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Regeneron	N/A	N/A	\$600.00	1	5/6/2021	Report M0244 with Q0243 as well as Q0244 for home/residence administration
8	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	BAMLANIVIMAB 700MG/20ML Solution	00002-7910-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	ETESEVIMAB 35MG/ML Solution	00002-7950-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
9	M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	Eli Lilly	N/A	N/A	\$360.00	1	2/9/2021	Report M0245 with Q0245
10	M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Eli Lilly	N/A	N/A	\$600.00		5/6/2021	Report M0246 with Q0245 for home/residence administration
11	Q0247	Sotrovimab, 500 mg	GSK	SOTROVIMAB 500MG/8ML Solution	00173-0901-86	\$0.00	1	5/26/2021	Report Q0247 with administration codes M0247, M0248
12	M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	GSK	N/A	N/A	\$360.00		5/26/2021	Report M0247 with Q0247
13	M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	GSK	N/A	N/A	\$600.00		5/26/2021	Report M0248 with Q0247 for home/residence administration
14	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 20MG/ML Solution	50242-0135-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 200MG/10ML Solution	50242-0136-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 400MG/20ML Solution	50242-0137-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250

COVID-19 Vaccines & Treatments									
Revised: January 1, 2022									
Submit claim for administration fee with the appropriate vaccine or monoclonal antibody CPT or HCPCS Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
15	M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0249 with Q0294 - 1st dose
16	M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0250 with Q0294 - 2nd dose
17	Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	Astra Zeneca	EVUSHELD 150-150MG/1.5ML Solution	00310-7442-02	\$0.00	1	12/8/2022	Report Q0220 with administration codes M0220, M0221
18	M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	Astra Zeneca	N/A	N/A	\$120.00	1	12/8/2020	Report M0220 with Q0220
19	M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Astra Zeneca	N/A	N/A	\$200.00	1	12/8/2020	Report M0220 with Q0220 for home administration